ETNI Entest Group Inc (CE)

Entest BioMedical Inc. (PINKSHEETS: ENTB) (OTCQB: ENTB) a company focused on veterinary biotechnology and veterinary hospital acquisition / operation, announced today that it has begun the process of interviewing qualified candidates to fill the Company's newly created position of Director of Corporate Affairs.

A Company spokesman stated that, "The primary responsibilities of the Director of Corporate Affairs shall be to identify veterinary hospitals suitable for acquisition, substantially assist in the structuring of those acquisitions, and work with the company to integrate newly acquired veterinary hospitals into the Company. The Company's current business model involves acquiring veterinary clinics / hospitals to be utilized as potential distribution channels for its products under development. The Company believes that, in addition to serving as distribution channels for the Company's immuno-therapeutic cancer vaccine for canines, these clinics will be able to generate revenue for the Company from current operations."

"Our primary goal is to continue growing the number of Veterinary Hospitals we own," stated Dr. David Koos, Chairman and CEO of Entest BioMedical. "In pursuing this segment of our business model, we will be able to continue growing our asset base, increase our current revenue stream and establish an initial distribution channel for our products and therapies; the first of these products being Entest's ImenVax immune-therapeutic canine cancer vaccine currently under development. Having a qualified Director of Corporate Affairs whose duties will consist primarily of identifying hospitals for acquisition and who possesses the skills required to substantially assist us in negotiating favorable purchase terms will be valuable in assisting the Company in achieving its goal of acquiring up to 10 additional veterinary clinics within the next 16 months." Entest currently owns and operates the McDonald Animal Hospital of Santa Barbara, CA which the company purchased in 2011. This facility serves as both a revenue source for Entest as well as a research facility for the biomedical company.

Dr. Koos continued, "One in every three dogs will develop cancer during its lifetime. Sadly, such cancers kill nearly half of all pet dogs over the age of ten; animals that are family to millions of pet owners. Pet owners are willing to pay the cost for the necessary treatments meant to save the lives of their loved ones. We believe we will be able to provide families the needed cancer therapies for their canines, within the appropriate facilities, should we continue pursuing our growth model. With the ASPCA citing approximately 78 million dogs as pets within the United States, the veterinary care market represents enormous revenue potential. It has been estimated that the U.S. market for veterinary cancer care amounts to approximately $300 million per year."

Dr. Koos concluded, "Canine cancer impacts 60% of all dogs over six years of age in the United States (http://dogcanceradvice.com/canine-cancer-information/overview/). Cancer in canines is still predominantly treated through surgical excision, chemotherapy and radiation therapy. These treatment methods can be highly invasive and can result in numerous unpleasant side effects. We believe our products under development, which utilize the patient's own immune system to battle the cancer, will be able to offer a lower cost, less traumatic alternative to veterinarians and pet owners. As both the CEO of Entest and a loving pet owner my objectives are twofold; to contribute economic value to Entest as well as to contribute to the lifelong happiness of families who are pet owners."

About Entest BioMedical Inc.:

Entest BioMedical Inc. (PINKSHEETS: ENTB) (OTCQB: ENTB) is a developer of veterinary medicines that harness the animal's own reparative / immunological mechanisms. The company's products include an immuno-therapeutic cancer vaccine for canines (ImenVax™). The company's immuno-therapeutic cancer vaccine utilizes an encapsulation device as the vaccine delivery system and requires a simple implant procedure.

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact: Entest BioMedical Inc. David R. Koos Chairman & CEO 619.702.1404 Direct 619.330.2328 Fax Email Contact www.EntestBio.com